Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited is set to announce its annual financial results for the year ending June 30, 2024, on August 29, 2024, accompanied by a webinar for investors and analysts. The company, known for its innovative photomedicine treatments and the first systemic photoprotective drug SCENESSE®, operates globally with a focus on serious and acute disorders. Registration for the webinar, where participants can submit questions in advance or during the session, is now open via the company’s website.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
